Historical hum News Stories
Humana: Medicare Overpayment Probe Shakes Stocks!!
This article summarizes the week’s concrete developments influencing Humana (HUM): renewed regulatory scrutiny over Medicare Advantage overpayments, recent institutional moves, and analyst adjustments. It explains how a $7B overpayment finding, a Piper Sandler price-target lift, and mixed pension/trading activity could affect Humana’s near-term performance and medium-term outlook.
Humana Q1 Beat; Lowers GAAP Guidance, MA Pain Now.
Humana beat Q1 adjusted EPS but trimmed GAAP guidance as Medicare Advantage margin pressures and Star Ratings headwinds compress near-term GAAP results. CMS's 2.48% MA rate increase for 2027 and management’s plan to restore MA margins to ~3% by 2028 offer offsetting medium-term tailwinds. This article breaks down the concrete drivers, financial impacts, and what investors should track next.
Humana (HUM) Pre-Treatment Review Shift
This article explains last week’s concrete developments affecting Humana (HUM): the insurer-led move to standardize pre-treatment reviews starting 2027 and industry forecasts of higher medical cost ratios for Q1. It assesses how these events may influence Humana’s operations, margins and near-term stock catalysts.
Humana Faces 2026 Pressure: CMS Rates & Star Hit!!
Humana’s stock remains under pressure after CMS’s muted Medicare Advantage rate proposal, a multi-billion-dollar Star Ratings headwind, and company moves to shrink unprofitable footprints and cut benefits. With no major new headlines this week, investors are focused on upcoming Q1 results and the final 2027 MA rate decision.
Humana Faces Margin Pressure, Raises Liquidity Now
This week Humana (HUM) saw an analyst price-target cut, a $1B debt raise, reaffirmed 2026 guidance, network changes in Florida, and notable Medicare Advantage enrollment gains — all driving near-term stock volatility and strategic adjustments.
Humana Faces Short-Term Pain, Picks Up $1B Cash Q1
This week Humana (HUM) moved to bolster liquidity with a $1.0B junior subordinated notes offering while reporting a Q4 2025 loss and sharply lowered 2026 EPS guidance. Key drivers are Medicare Advantage Star Ratings, CMS rate actions, and elevated medical costs. Investors should watch upcoming CMS decisions, Star Ratings updates, and early 2026 operating metrics as potential catalysts for a recovery.
Humana $1B Notes and OIG Probe: What It Means Now!
This article examines Humana’s recent $1 billion subordinated note offering and the OIG findings on unsupported Medicare Advantage diagnosis payments, explaining immediate financial and regulatory implications for HUM stock and what investors should monitor next.
Humana Plunges: $3.5B Star-Rating Shock Hits Stock
Humana shares plunged after the company disclosed a $3.5B Medicare Advantage Star Ratings headwind, conservative 2026 guidance, an exit from unprofitable counties and a CMS proposal that implied nearly flat MA payment rates — all amplifying pressure on HUM stock.
Humana Faces $3.5B Headwind; HUM Rebounds Star Cut
Humana (HUM) recently weathered a steep selloff after a CMS rate surprise and conservative 2026 guidance tied to a $3.5 billion Medicare Advantage Star Ratings shortfall. The company has taken concrete steps—county exits and benefit trims—while investors reacted with a multi-day rebound. Key near-term catalysts include CMS final 2027 rates and execution on CenterWell-driven cost and quality improvements.
Humana Slides on $3.5B Star-Ratings Hit
Humana reported conservative 2026 guidance after Q4 results, citing a $3.5 billion headwind from lower Medicare Advantage Star Ratings. Strong membership growth contrasts with margin pressure driven by lost bonus payments and a muted CMS reimbursement update, prompting operational cuts and a sharp drop in HUM shares.
Humana Falls After Medicare Advantage Rate Cut Now
Humana shares dropped sharply this week following a modest Medicare Advantage rate proposal and renewed risk-adjustment scrutiny. The 0.9% proposed rate increase for 2027 and related policy pressures are creating tangible margin risk for Humana, which is heavily exposed to Medicare Advantage enrollment.